Literature DB >> 7910854

Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells.

Z Dong1, R Radinsky, D Fan, R Tsan, C D Bucana, C Wilmanns, I J Fidler.   

Abstract

BACKGROUND: The major cause of death from cancer is metastases that are resistant to conventional therapies. The resistance of metastatic tumor cells to chemotherapy can be caused by their intrinsic properties, such as increased expression of the mdr genes.
PURPOSE: The purpose of our present study was to determine some of the mechanisms by which the organ microenvironment influences the response of tumor cells to chemotherapy.
METHODS: Murine CT-26 colon cancer cells growing in continuous culture (parental cells) were harvested and injected subcutaneously into the lateral flank (to produce subcutaneous tumors) or the lateral tail vein (to produce experimental lung metastases) of 10 8-week-old syngeneic male BALB/c mice. Seven days after tumor-cell injection, the mice were given intravenous injections of either doxorubicin (10 mg/kg) or 0.9% NaCl (controls). This in vivo injection was repeated 7 days later. Mice with subcutaneous tumors and lung metastases were killed by cervical dislocation on day 21, and tumor samples from control mice were harvested and adapted to culture. The sensitivity of the cultured cells to doxorubicin and fluorouracil (5-FU) was determined at multiple time points. Levels of mdr-1 DNA were measured by slot-blot and Southern-blot analyses. mdr mRNA expression levels were measured by Northern-blot analysis using mdr-1- and mdr-3-specific hybridization probes, and P-glycoprotein level was determined by fluorescence-activated cell sorting using different monoclonal antibodies.
RESULTS: Treatment with doxorubicin produced 80% growth inhibition of CT-26 subcutaneous tumors but had little effect on the number (and size) of experimental lung metastases. Collectively, the results suggest that the multidrug-resistant phenotype developed in CT-26 cells growing in the lung environment. Cultures established from lung metastases were initially resistant to doxorubicin (but not to 5-FU) and showed elevated expression of mdr-1 mRNA transcripts and P-glycoprotein. This resistance could be overcome by verapamil and disappeared after 21 days in culture. No mdr gene amplification was detected. The expression level of mdr-specific mRNA (predominance of mdr-1) and P-glycoprotein was directly associated with resistance to doxorubicin.
CONCLUSIONS: Results of this study have demonstrated that the in vivo sensitivity of murine CT-26 colon carcinoma cells to doxorubicin depends on the organ environment. The organ environment can influence the P-glycoprotein-mediated multidrug-resistant phenotype in tumor cells, and the increased expression of P-glycoprotein is transient; once removed from the environment (lung), the cell's resistance reverts to that of the sensitive parent cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910854     DOI: 10.1093/jnci/86.12.913

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  27 in total

1.  Is tail vein injection a relevant breast cancer lung metastasis model?

Authors:  Omar M Rashid; Masayuki Nagahashi; Suburamaniam Ramachandran; Catherine I Dumur; Julia C Schaum; Akimitsu Yamada; Tomoyoshi Aoyagi; Sheldon Milstien; Sarah Spiegel; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 2.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

3.  Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma.

Authors:  Eric M Mastria; Mingnan Chen; Jonathan R McDaniel; Xinghai Li; Jinho Hyun; Mark W Dewhirst; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-01-28       Impact factor: 9.776

4.  In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells.

Authors:  Y Kitadai; C D Bucana; L M Ellis; H Anzai; E Tahara; I J Fidler
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

5.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging.

Authors:  A Rehemtulla; L D Stegman; S J Cardozo; S Gupta; D E Hall; C H Contag; B D Ross
Journal:  Neoplasia       Date:  2000 Nov-Dec       Impact factor: 5.715

6.  Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Melinda Hollingshead; Glenn Merlino
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

7.  Influence of the host microenvironment on the clonal selection of human colon carcinoma cells during primary tumor growth and metastasis.

Authors:  R K Singh; R Tsan; R Radinsky
Journal:  Clin Exp Metastasis       Date:  1997-03       Impact factor: 5.150

8.  Animal models of cancer in the head and neck region.

Authors:  Seungwon Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-06-27       Impact factor: 3.372

Review 9.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

Review 10.  Integrating evolutionary dynamics into cancer therapy.

Authors:  Robert A Gatenby; Joel S Brown
Journal:  Nat Rev Clin Oncol       Date:  2020-07-22       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.